From: Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
Age groups (years)
PCV13
PPSV23
IPD [14],[33],[34]
Inpatient pneumonia [28]
Outpatient pneumonia [10]
IPD [26],[27],[31],[32]
Inpatient pneumonia [37]-[42]
Outpatient pneumonia [37]-[42]
50 – 64
88.9%
24.2%
5.6%
79.2%
0.0%
65 – 74
81.5%
21.9%
5.1%
61.6%
75 – 79
75.7%
20.2%
4.7%
50.4%
80 – 99
70.3%
18.7%
4.3%
42.1%